Reducing the risk of endophthalmitis following intravitreal injections.
about
Clinical development of new treatments for diabetic macular oedemaComparative safety and tolerability of anti-VEGF therapy in age-related macular degenerationExogenous endophthalmitis in diabetic patients: a systemic reviewEndophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive reviewBranch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalitiesRisk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.Toll-like receptor 2 ligand-induced protection against bacterial endophthalmitisIntraoperative usefulness and postoperative results of the endoilluminator for performing primary posterior capsulectomy and anterior vitrectomy during pediatric cataract surgery.Effects of moxifloxacin exposure on the conjunctival flora and antibiotic resistance profile following repeated intravitreal injectionsEndophthalmitis: state of the art.A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications.The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trialsTopical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injectionEvaluation of tissue interactions with mechanical elements of a transscleral drug delivery device.Endophthalmitis after intravitreal injections.Drug safety evaluation of intravitreal triamcinolone acetonide.Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literatureComplications of intravitreal injections in patients with diabetes.Ocular Infection: EndophthalmitisRetinal Diseases Associated with Oxidative Stress and the Effects of a Free Radical Scavenger (Edaravone).Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis.Case of endophthalmitis following intravitreal injections of bevacizumab.Pharmacotherapeutic efficacy of preservative-free intravitreal triamcinolone acetonide.Endoilluminator-assisted pediatric cataract surgery with hazy corneaBakterielle Kontamination von Injektionskanülen nach intravitrealer operativer Medikamenteneingabe in ParaguayIntravitreal steroids for the treatment of retinal diseases
P2860
Q26825365-6F49EDAE-8DD8-4A1D-8FE6-50CEACBD995CQ26852289-47A68AD3-A696-41D8-9C0C-CC08B6D83B24Q26859314-44A7CFE7-2659-4EA5-83A6-99A4F1691053Q28084070-F3D8D267-1160-43ED-A7BE-583C15676378Q33320830-7214F15B-18EF-4FB2-89A4-B568EA2BF696Q33518324-DF3F6E0F-D572-42CD-B0C4-789B0A94B8FFQ33556991-833D58F6-AF41-4DC2-95F0-47F19217EA26Q34055064-AF1AB151-5BCC-46E4-9E8A-57D33D89BA96Q34390583-4FD64842-359B-42D1-B4A3-431F667FC33CQ34952098-ACD3DEDA-49D0-4CC9-9AAE-6DAF4C928990Q35226722-B07CA2D1-13B8-4434-B679-AC75925F790CQ36120654-A5917C82-633F-4D1C-8288-1D22F9EA1FC6Q36326803-60A9702F-7FC7-4201-8EEE-BA5050DAE5BFQ37327804-79C46176-BF83-499F-9C2F-6CA9B7E5817FQ37544827-4216684D-7447-415E-86BB-770DE213ABCEQ37953969-5C0B17AC-406F-4EEB-AA2E-497C2C02EF89Q38110731-71EB9F5B-4294-4100-81E1-54C6D7D48A3AQ38261106-FD3F90AE-35E4-4269-A9D7-BCC2F00A9D5AQ38616486-FE8A34D5-2CAD-4084-93D0-E7427328D193Q38963088-35BDBC57-D0E4-43C1-A93F-487D2837B948Q41878765-929683BE-7F2D-43D3-89B1-41EFA81D0D2DQ42581034-5315753A-2503-410B-B1D6-140D46B6742BQ43225793-DB7E9382-D0B6-45E1-AB49-238FF9756A06Q58806272-6498C620-432D-42A7-B191-2EC91E92CCA6Q58832340-590970BB-E24C-4ACA-A577-D1799020CE8FQ59101228-07C9B1C4-A30E-4B69-B863-A2E7ABF7557C
P2860
Reducing the risk of endophthalmitis following intravitreal injections.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Reducing the risk of endophthalmitis following intravitreal injections.
@en
Reducing the risk of endophthalmitis following intravitreal injections.
@nl
type
label
Reducing the risk of endophthalmitis following intravitreal injections.
@en
Reducing the risk of endophthalmitis following intravitreal injections.
@nl
prefLabel
Reducing the risk of endophthalmitis following intravitreal injections.
@en
Reducing the risk of endophthalmitis following intravitreal injections.
@nl
P1433
P1476
Reducing the risk of endophthalmitis following intravitreal injections.
@en
P2093
Harry W Flynn
Ingrid U Scott
P356
10.1097/IAE.0B013E3180307271
P577
2007-01-01T00:00:00Z